148 related articles for article (PubMed ID: 18446196)
1. Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials.
Stevens W; Kamali A; Karita E; Anzala O; Sanders EJ; Jaoko W; Kaleebu P; Mulenga J; Dally L; Fast P; Gilmour J; Farah B; Birungi J; Hughes P; Manigart O; Stevens G; Yates S; Thomson H; von Lieven A; Krebs M; Price MA; Stoll-Johnson L; Ketter N
PLoS One; 2008 Apr; 3(4):e2043. PubMed ID: 18446196
[TBL] [Abstract][Full Text] [Related]
2. CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.
Karita E; Ketter N; Price MA; Kayitenkore K; Kaleebu P; Nanvubya A; Anzala O; Jaoko W; Mutua G; Ruzagira E; Mulenga J; Sanders EJ; Mwangome M; Allen S; Bwanika A; Bahemuka U; Awuondo K; Omosa G; Farah B; Amornkul P; Birungi J; Yates S; Stoll-Johnson L; Gilmour J; Stevens G; Shutes E; Manigart O; Hughes P; Dally L; Scott J; Stevens W; Fast P; Kamali A
PLoS One; 2009; 4(2):e4401. PubMed ID: 19197365
[TBL] [Abstract][Full Text] [Related]
3. Effect of seasonal variation on adult clinical laboratory parameters in Rwanda, Zambia, and Uganda: implications for HIV biomedical prevention trials.
Ruzagira E; Abaasa A; Karita E; Mulenga J; Kilembe W; Allen S; Bahemuka U; Bwanika AN; Levin J; Price MA; Kamali A
PLoS One; 2014; 9(8):e105089. PubMed ID: 25118593
[TBL] [Abstract][Full Text] [Related]
4. Haematological and biochemistry laboratory abnormalities associated with splenomegaly in asymptomatic adults in Masaka, Uganda: implications for HIV biomedical prevention trials.
Ruzagira E; Abaasa A; Levin J; Bahemuka U; Bwanika A; Amornkul PN; Price MA; Grosskurth H; Kamali A
Trop Med Int Health; 2010 Jan; 15(1):105-12. PubMed ID: 19968840
[TBL] [Abstract][Full Text] [Related]
5. Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya.
Omosa-Manyonyi GS; Jaoko W; Anzala O; Ogutu H; Wakasiaka S; Malogo R; Nyange J; Njuguna P; Ndinya-Achola J; Bhatt K; Farah B; Oyaro M; Schmidt C; Priddy F; Fast P
PLoS One; 2011 Jan; 6(1):e14580. PubMed ID: 21283743
[TBL] [Abstract][Full Text] [Related]
6. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand.
Jenkins RA; Chinaworapong S; Morgan PA; Ruangyuttikarn C; Sontirat A; Chiu J; Michael RA; Nitayaphan S; Khamboonruang C
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):171-7. PubMed ID: 9637582
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa.
Schmidt C; Jaoko W; Omosa-Manyonyi G; Kaleebu P; Mpendo J; Nanvubya A; Karita E; Bayingana R; Bekker LG; Chomba E; Kilembe W; Nchabeleng M; Nyombayire J; Stevens G; Chetty P; Lehrman J; Cox J; Allen S; Dally L; Smith C; Fast PE
Hum Vaccin Immunother; 2014; 10(3):714-23. PubMed ID: 24374365
[TBL] [Abstract][Full Text] [Related]
8. Representation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City.
Ellman TM; Hawkins K; Benitez J; Negron R; Chang S; Palmer S; Robertson V; Chiasson MA; Sobieszczyk ME
Vaccine; 2015 Nov; 33(48):6809-15. PubMed ID: 26458799
[TBL] [Abstract][Full Text] [Related]
9. Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya.
Nyaoke BA; Mutua GN; Sajabi R; Nyasani D; Mureithi MW; Anzala OA
PLoS One; 2017; 12(9):e0183788. PubMed ID: 28880880
[TBL] [Abstract][Full Text] [Related]
10. Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa.
Kibuuka H; Guwatudde D; Kimutai R; Maganga L; Maboko L; Watyema C; Sawe F; Shaffer D; Matsiko D; Millard M; Michael N; Wabwire-Mangen F; Robb M
PLoS One; 2009; 4(4):e5164. PubMed ID: 19360102
[TBL] [Abstract][Full Text] [Related]
11. Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals.
Schmidt BM; Tameris M; Geldenhuys H; Luabeya A; Bunyasi E; Hawkridge T; McClain JB; Mahomed H; Scriba TJ; McShane H; Hatherill M
Trop Med Int Health; 2018 Jan; 23(1):63-68. PubMed ID: 29140587
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of locally established reference intervals for hematology and biochemistry parameters in Western Kenya.
Odhiambo C; Oyaro B; Odipo R; Otieno F; Alemnji G; Williamson J; Zeh C
PLoS One; 2015; 10(4):e0123140. PubMed ID: 25874714
[TBL] [Abstract][Full Text] [Related]
13. Reasons for declining to enroll in a phase I and II HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, Tanzania.
Tarimo EA; Thorson A; Kohi TW; Bakari M; Mhalu F; Kulane A
PLoS One; 2011 Feb; 6(2):e14619. PubMed ID: 21358826
[TBL] [Abstract][Full Text] [Related]
14. Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial.
Bakari M; Munseri P; Francis J; Aris E; Moshiro C; Siyame D; Janabi M; Ngatoluwa M; Aboud S; Lyamuya E; Sandström E; Mhalu F
BMC Public Health; 2013 Dec; 13():1149. PubMed ID: 24321091
[TBL] [Abstract][Full Text] [Related]
15. Seroincidence of HIV-1 infection in African women of reproductive age: a prospective cohort study in Kigali, Rwanda, 1988-1992.
Leroy V; Van de Perre P; Lepage P; Saba J; Nsengumuremyi F; Simonon A; Karita E; Msellati P; Salamon R; Dabis F
AIDS; 1994 Jul; 8(7):983-6. PubMed ID: 7946110
[TBL] [Abstract][Full Text] [Related]
16. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
Adis International Ltd
Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
[TBL] [Abstract][Full Text] [Related]
17. Logics of Commitment in Vaccine Trials of the ANRS Cohorts 1992-2001.
Fillieule O
J Acquir Immune Defic Syndr; 2018 Oct; 79 Suppl 1():S59-S68. PubMed ID: 30222706
[TBL] [Abstract][Full Text] [Related]
18. Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa.
Hanass-Hancock J; Carpenter B; Reddy T; Nzuza A; Gaffoor Z; Goga A; Andrasik M
Trials; 2021 Dec; 22(1):897. PubMed ID: 34895272
[TBL] [Abstract][Full Text] [Related]
19. Risk behaviours and comprehension among intravenous drug users volunteered for HIV vaccine trial.
Pitisuttithum P; Migasena S; Laothai A; Suntharasamai P; Kumpong C; Vanichseni S
J Med Assoc Thai; 1997 Jan; 80(1):47-50. PubMed ID: 9078816
[TBL] [Abstract][Full Text] [Related]
20. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.
Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE
AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
